BIA
TEVA icon

Barry Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Barry Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-70,274
Closed -$1.24M – 77
2017
Q3 		$1.24M Sell
70,274
-56,063
-44% -$1.26M 0.46% 33
2017
Q2 		$4.2M Sell
126,337
-2,345
-2% -$72.6K 1.58% 22
2017
Q1 		$4.13M Buy
128,682
+16,053
+14% +$548K 1.53% 23
2016
Q4 		$4.08M Sell
112,629
-2,458
-2% -$98.1K 1.43% 24
2016
Q3 		$5.29M Buy
115,087
+15,739
+16% +$821K 1.82% 23
2016
Q2 		$4.99M Buy
99,348
+969
+1% +$51.6K 1.94% 22
2016
Q1 		$5.26M Buy
98,379
+2,687
+3% +$158K 1.67% 23
2015
Q4 		$6.28M Sell
95,692
-873
-0.9% -$54K 2.04% 17
2015
Q3 		$5.45M Buy
96,565
+1,657
+2% +$107K 1.75% 25
2015
Q2 		$0 Buy
94,908
+12,404
+15% +$765K ﹤0.01% 66
2015
Q1 		$5.14M Buy
82,504
+4,504
+6% +$262K 1.57% 25
2014
Q4 		$4.49M Buy
+78,000
New +$4.35M 1.46% 25

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Barry Investment Advisors's TEVA Position: Q4 2017 in Review

Barry Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 70,274 shares — an estimated $1.24M sold.

Barry Investment Advisors first reported a position in TEVA in Q4 2014 and held it in 12 quarters. The position peaked at $6.28M in Q4 2015. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Barry Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Barry Investment Advisors sold 70,274 Teva Pharmaceuticals shares in Q4 2017, an estimated $1.24M.
  • Barry Investment Advisors first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 12 quarters.
  • Barry Investment Advisors's Teva Pharmaceuticals position peaked at $6.28M in Q4 2015.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Barry Investment Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.